Titre:	GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms
Auteur(s):	Carvalho, Amandda Évelin Silva Braga, Luma Dayane Carvalho Filiú Bogéa, Gabriela Muller Reche Assis, Alan Jhones Barbosa de Silva, Fábio Pittella Araujo, Felipe Saldanha
metadata.dc.identifier.orcid:	https://orcid.org/0000-0002-4200-0821
metadata.dc.contributor.affiliation:	University of Brasília, Faculty of Health Sciences, Hematology and Stem Cells Laboratory University of Brasília, Faculty of Health Sciences, Hematology and Stem Cells Laboratory University of Brasília, Faculty of Health Sciences, Hematology and Stem Cells Laboratory University of Brasilia, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer University of Brasilia, Faculty of Health Sciences and Medicine, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Health Sciences, Hematology and Stem Cells Laboratory
Assunto::	Leucemia linfoblástica aguda (LLA) Leucemia linfocítica crônica (LLC) Neoplasmas
Date de publication:	jui-2024
Editeur:	Springer Nature
Référence bibliographique:	CARVALHO, Amandda Évelin Silva et al. GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms. Cancer Cell International, [S.l], v. 24, n. 243, 2024. DOI: https://doi.org/10.1186/s12935-024-03441-y. Disponível em: https://link.springer.com/article/10.1186/s12935-024-03441-y. Acesso em: 13 abr. 2026.
Abstract:	Histone methyltransferases (HMTs) are enzymes that regulate histone methylation and play an important role in controlling transcription by altering the chromatin structure. Aberrant activation of HMTs has been widely reported in certain types of neoplastic cells. Among them, G9a/EHMT2 and GLP/EHMT1 are crucial for H3K9 methylation, and their dysregulation has been associated with tumor initiation and progression in different types of cancer. More recently, it has been shown that G9a and GLP appear to play a critical role in several lymphoid hematologic malignancies. Importantly, the key roles played by both enzymes in various diseases made them attractive targets for drug development. In fact, in recent years, several groups have tried to develop small molecule inhibitors targeting their epigenetic activities as potential anticancer therapeutic tools. In this review, we discuss the physiological role of GLP and G9a, their oncogenic functions in hematologic malignancies of the lymphoid lineage, and the therapeutic potential of epigenetic drugs targeting G9a/GLP for cancer treatment.
metadata.dc.description.unidade:	Faculdade de Ciências da Saúde (FS) Departamento de Farmácia (FS FAR)
metadata.dc.description.ppg:	Programa de Pós-Graduação em Ciências Farmacêuticas
Licença::	The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data
DOI:	https://doi.org/10.1186/s12935-024-03441-y
metadata.dc.relation.publisherversion:	https://link.springer.com/article/10.1186/s12935-024-03441-y
Collection(s) :	Artigos publicados em periódicos e afins

Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.